John Capek - Abbott Laboratories Insider

Abbott Laboratories -- Brazil Stock  

BRL 45.52  0.00  0.00%

Executive VP of Ventures

Dr. John M. Capek, Ph.D. is Executive Vice President Ventures of the Company. Previously, he served as Senior Vice President, Abbott Vascular, heading up Abbott global vascular business. Dr. Capek served in various management roles at Guidant, including president, Guidant Vascular Intervention and Vice President and General Manager of Bioabsorbable Vascular Solutions. He also served as Vice President and General Manager of Guidant Germany and Vice President, Marketing, Guidant Cardiac Rhythm Management Group. Before joining Guidant, Dr. Capek was manager of New Product Technology at Eli Lilly Company
Age: 54  EVP Since 2015      
224-667-6100  http://www.abbott.com
Capek has a Bachelor degree in Biomedical Engineering, a Master degree in Biomedical Engineering, a Master degree in Electrical Engineering, a Ph.D. in Biomedical Engineering and a Master degree in Business Administration from Rensselaer Polytechnic Institute.

Management Efficiency

The company has return on total asset (ROA) of 3.45 % which means that it generated profit of $3.45 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 4.05 % meaning that it generated $4.05 on every $100 dollars invested by stockholders.
The company has accumulated 24.09 B in total debt with debt to equity ratio (D/E) of 75.7 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Abbott Laboratories has Current Ratio of 2.88 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Abbott Laboratories manufactures and sells health care solutions worldwide. Abbott Laboratories (ABTT34) is traded on Sao Paolo Stock Exchange in Brazil. It is located in Abbott Park, IL and employs 74,000 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Abbott Laboratories to your portfolio

Top Management

Abbott Laboratories Leadership Team
Scott White, President
Samuel Scott, Director
Deepak Nath, President
Jaime Contreras, President
Roger Bird, President
Nancy McKinstry, Director
Heather Mason, President
James Farrell, Director
J White, President
Phebe Novakovic, Director
JeanYves Pavee, President
Andrew Lane, President
Roxanne Austin, Director
Georges Vos, President
Stephen Fussell, President
Thomas Freyman, EVP
Sally Blount, Director
Daniel Starks, Director
Thomas Frinzi, President
Eric Fain, President
John Capek, EVP
Robert Alpern, Director, Ph.D
Murthy Simhambhatla, President
Miles White, Chairman
Robert Ford, President
Glenn Tilton, Director
Richard Ashley, EVP
Michael Rousseau, President
Edward Liddy, Director
Hubert Allen, EVP
Charles Foltz, President
Brian Yoor, CFO
John Stratton, Director
Joseph Manning, President
Jared Watkin, President
William Osborn, Director
Brian Blaser, EVP
Michael Warmuth, President
Robert Funck, President
Daniel Salvadori, President
W Farrell, Director

Stock Performance

Abbott Laboratories Performance Indicators